Multiagent chemotherapy in relapsing ovarian cancer

E. A. Surwit, David S Alberts, W. Crisp, R. A. Jackson, P. N. Grozea, S. Leigh

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

A multiagent regimen (vinblastine, bleomycin, hexamethylmelamine, and cis-platinum) partly designed on the basis of data from a human tumor stem cell assay was used to treat 36 patients with relapsing epithelial ovarian cancer. All patients included in this study had previously received alkylating agent therapy, and 78% (28/36) had also received Adriamycin. Thirty-five patients were clinically evaluable for response; eight achieved complete clinical remission, and nine achieved partial remission, for an overall response rate of 49%. The median duration of response was 10 months, and three of the complete responders are in remission at 10+, 17+, and 22+ months. Mild to moderate peripheral neuropathy was the major side effect, occurring in 11% (4/35) of patients. Myelotoxicity was well tolerated. We conclude that this four-drug regimen is effective in the treatment of relapsing ovarian cancer patients and should be considered for study as a front-line combination chemotherapy for previously untreated patients.

Original languageEnglish (US)
Pages (from-to)613-616
Number of pages4
JournalAmerican Journal of Obstetrics and Gynecology
Volume146
Issue number6
StatePublished - 1983

Fingerprint

Ovarian Neoplasms
Drug Therapy
Tumor Stem Cell Assay
Altretamine
Vinblastine
Alkylating Agents
Bleomycin
Peripheral Nervous System Diseases
Combination Drug Therapy
Doxorubicin
Cisplatin
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Surwit, E. A., Alberts, D. S., Crisp, W., Jackson, R. A., Grozea, P. N., & Leigh, S. (1983). Multiagent chemotherapy in relapsing ovarian cancer. American Journal of Obstetrics and Gynecology, 146(6), 613-616.

Multiagent chemotherapy in relapsing ovarian cancer. / Surwit, E. A.; Alberts, David S; Crisp, W.; Jackson, R. A.; Grozea, P. N.; Leigh, S.

In: American Journal of Obstetrics and Gynecology, Vol. 146, No. 6, 1983, p. 613-616.

Research output: Contribution to journalArticle

Surwit, EA, Alberts, DS, Crisp, W, Jackson, RA, Grozea, PN & Leigh, S 1983, 'Multiagent chemotherapy in relapsing ovarian cancer', American Journal of Obstetrics and Gynecology, vol. 146, no. 6, pp. 613-616.
Surwit EA, Alberts DS, Crisp W, Jackson RA, Grozea PN, Leigh S. Multiagent chemotherapy in relapsing ovarian cancer. American Journal of Obstetrics and Gynecology. 1983;146(6):613-616.
Surwit, E. A. ; Alberts, David S ; Crisp, W. ; Jackson, R. A. ; Grozea, P. N. ; Leigh, S. / Multiagent chemotherapy in relapsing ovarian cancer. In: American Journal of Obstetrics and Gynecology. 1983 ; Vol. 146, No. 6. pp. 613-616.
@article{5b3a60e603204f6f8a19983ac79be99d,
title = "Multiagent chemotherapy in relapsing ovarian cancer",
abstract = "A multiagent regimen (vinblastine, bleomycin, hexamethylmelamine, and cis-platinum) partly designed on the basis of data from a human tumor stem cell assay was used to treat 36 patients with relapsing epithelial ovarian cancer. All patients included in this study had previously received alkylating agent therapy, and 78{\%} (28/36) had also received Adriamycin. Thirty-five patients were clinically evaluable for response; eight achieved complete clinical remission, and nine achieved partial remission, for an overall response rate of 49{\%}. The median duration of response was 10 months, and three of the complete responders are in remission at 10+, 17+, and 22+ months. Mild to moderate peripheral neuropathy was the major side effect, occurring in 11{\%} (4/35) of patients. Myelotoxicity was well tolerated. We conclude that this four-drug regimen is effective in the treatment of relapsing ovarian cancer patients and should be considered for study as a front-line combination chemotherapy for previously untreated patients.",
author = "Surwit, {E. A.} and Alberts, {David S} and W. Crisp and Jackson, {R. A.} and Grozea, {P. N.} and S. Leigh",
year = "1983",
language = "English (US)",
volume = "146",
pages = "613--616",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Multiagent chemotherapy in relapsing ovarian cancer

AU - Surwit, E. A.

AU - Alberts, David S

AU - Crisp, W.

AU - Jackson, R. A.

AU - Grozea, P. N.

AU - Leigh, S.

PY - 1983

Y1 - 1983

N2 - A multiagent regimen (vinblastine, bleomycin, hexamethylmelamine, and cis-platinum) partly designed on the basis of data from a human tumor stem cell assay was used to treat 36 patients with relapsing epithelial ovarian cancer. All patients included in this study had previously received alkylating agent therapy, and 78% (28/36) had also received Adriamycin. Thirty-five patients were clinically evaluable for response; eight achieved complete clinical remission, and nine achieved partial remission, for an overall response rate of 49%. The median duration of response was 10 months, and three of the complete responders are in remission at 10+, 17+, and 22+ months. Mild to moderate peripheral neuropathy was the major side effect, occurring in 11% (4/35) of patients. Myelotoxicity was well tolerated. We conclude that this four-drug regimen is effective in the treatment of relapsing ovarian cancer patients and should be considered for study as a front-line combination chemotherapy for previously untreated patients.

AB - A multiagent regimen (vinblastine, bleomycin, hexamethylmelamine, and cis-platinum) partly designed on the basis of data from a human tumor stem cell assay was used to treat 36 patients with relapsing epithelial ovarian cancer. All patients included in this study had previously received alkylating agent therapy, and 78% (28/36) had also received Adriamycin. Thirty-five patients were clinically evaluable for response; eight achieved complete clinical remission, and nine achieved partial remission, for an overall response rate of 49%. The median duration of response was 10 months, and three of the complete responders are in remission at 10+, 17+, and 22+ months. Mild to moderate peripheral neuropathy was the major side effect, occurring in 11% (4/35) of patients. Myelotoxicity was well tolerated. We conclude that this four-drug regimen is effective in the treatment of relapsing ovarian cancer patients and should be considered for study as a front-line combination chemotherapy for previously untreated patients.

UR - http://www.scopus.com/inward/record.url?scp=0020531579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020531579&partnerID=8YFLogxK

M3 - Article

VL - 146

SP - 613

EP - 616

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 6

ER -